Cagrilintide to be investigated for reducing food intake and appetite in overweight or obese individuals

The global prevalence of overweight and obesity continues to rise, posing significant public health challenges due to associated comorbidities like type 2 diabetes and cardiovascular disease. Current pharmacological interventions often target incretin pathways, but there remains a need for diverse mechanisms to improve treatment efficacy and patient response. Amylin, a neuroendocrine hormone co-secreted with insulin from pancreatic beta cells, plays a crucial role in regulating glucose homeostasis, gastric emptying, and satiety. Analogs like cagrilintide aim to leverage this natural pathway to enhance feelings of fullness and reduce caloric intake, offering a potentially complementary or alternative approach to weight management.

This upcoming Phase 1, randomized, quadruple-blinded, placebo-controlled clinical trial will enroll an estimated 120 participants with overweight or obesity. Participants will be assigned to receive either Cagrilintide or a matched placebo, administered subcutaneously once weekly for up to 17 weeks. The total study duration for each participant will be approximately 30 weeks. The primary objective is to assess the effect of Cagrilintide on energy intake and appetite, providing initial insights into its pharmacological profile and safety in humans. This design is standard for early-phase trials evaluating novel compounds.

As this study is NOT_YET_RECRUITING and scheduled to commence in April 2026, no findings are available at this time. The trial's primary goal is to gather initial data on cagrilintide's effects on energy intake and appetite, alongside safety and tolerability, which are foundational for subsequent clinical development phases. > The study aims to establish a preliminary understanding of how cagrilintide modulates physiological responses related to food consumption in humans.